Erwin G Van Meir

List of Publications by Citations

Source: https://exaly.com/author-pdf/8351488/erwin-g-van-meir-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 75 | 9,246 | 39 | 77 |
|-------------------|-----------------------|---------------------|-----------------|
| papers | citations | h-index | g-index |
| 77 ext. papers | 10,870 ext. citations | 12.2 avg, IF | 5.35 L-index |

| # | Paper | IF | Citations |
|----|--|-------|-----------|
| 75 | The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77 | 56.2 | 2900 |
| 74 | Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010 , 60, 166-93 | 220.7 | 950 |
| 73 | The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. <i>Neuro-Oncology</i> , 2005 , 7, 122-33 | 1 | 527 |
| 72 | Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6 | 24.3 | 511 |
| 71 | Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. <i>Brain Pathology</i> , 1999 , 9, 469-79 | 6 | 424 |
| 70 | Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. <i>International Journal of Biochemistry and Cell Biology</i> , 2004 , 36, 1046-69 | 5.6 | 391 |
| 69 | Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. <i>Genome Research</i> , 2015 , 25, 316-27 | 9.7 | 240 |
| 68 | Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016 , 529, 351-7 | 50.4 | 206 |
| 67 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 484-495 | 21.7 | 187 |
| 66 | Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. <i>Molecular Cell</i> , 2014 , 53, 534-48 | 17.6 | 184 |
| 65 | Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. <i>Oncogene</i> , 2005 , 24, 3632-42 | 9.2 | 140 |
| 64 | Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. <i>International Journal of Cancer</i> , 1994 , 58, 240-7 | 7.5 | 131 |
| 63 | Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. <i>International Journal of Cancer</i> , 1998 , 79, 640-4 | 7.5 | 130 |
| 62 | p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. <i>Oncogene</i> , 2000 , 19, 3816-22 | 9.2 | 120 |
| 61 | Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene, 1999 , 18, 1447-56 | 9.2 | 103 |
| 60 | Hypoxia inducible factor-1: a novel target for cancer therapy. <i>Anti-Cancer Drugs</i> , 2005 , 16, 901-9 | 2.4 | 100 |
| 59 | Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. <i>Future Medicinal Chemistry</i> , 2013 , 5, 553-72 | 4.1 | 93 |

(1997-2009)

| 58 | Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. <i>Cancer Research</i> , 2009 , 69, 1212-20 | 10.1 | 85 |
|----|---|------------------|----|
| 57 | Identification of a novel small molecule HIF-1alpha translation inhibitor. <i>Clinical Cancer Research</i> , 2009 , 15, 6128-36 | 12.9 | 84 |
| 56 | Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. <i>American Journal of Pathology</i> , 2003 , 162, 19-27 | 5.8 | 82 |
| 55 | Cytokines and tumors of the central nervous system. <i>Glia</i> , 1995 , 15, 264-88 | 9 | 81 |
| 54 | Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. <i>Advances in Anatomic Pathology</i> , 2002 , 9, 24-36 | 5.1 | 73 |
| 53 | Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. <i>Journal of Molecular Medicine</i> , 2012 , 90, 1161-1171 | 5.5 | 70 |
| 52 | Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. <i>Cancer Research</i> , 2014 , 74, 4536-48 | 10.1 | 68 |
| 51 | Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. <i>Cancer Research</i> , 2006 , 66, 11991-7 | 10.1 | 68 |
| 50 | Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. <i>Oncogene</i> , 1999 , 18, 5870-8 | 9.2 | 68 |
| 49 | Tumor initiating cells in malignant gliomas: biology and implications for therapy. <i>Journal of Molecular Medicine</i> , 2009 , 87, 363-74 | 5.5 | 67 |
| 48 | Biology of advanced uveal melanoma and next steps for clinical therapeutics. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 135-47 | 4.5 | 62 |
| 47 | Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 Interaction with cofactors p300/CBP. <i>Clinical Cancer Research</i> , 2012 , 18, 6623-33 | 12.9 | 61 |
| 46 | Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. <i>Clinical Cancer Research</i> , 2004 , 10, 8603-12 | 12.9 | 60 |
| 45 | Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. <i>Oncogene</i> , 2001 , 20, 1103- | -8 ^{.2} | 58 |
| 44 | Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. <i>Journal of Molecular Medicine</i> , 2011 , 89, 743-52 | 5.5 | 52 |
| 43 | p53 and brain tumors: from gene mutations to gene therapy. <i>Brain Pathology</i> , 1998 , 8, 599-613 | 6 | 50 |
| 42 | Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. <i>Cancer Research</i> , 2011 , 71, 5859-70 | 10.1 | 49 |
| 41 | New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. <i>Oncogene</i> , 1997 , 15, 997-1000 | 9.2 | 47 |

| 40 | Adhesion GPCRs in Tumorigenesis. <i>Handbook of Experimental Pharmacology</i> , 2016 , 234, 369-396 | 3.2 | 44 |
|----|--|-------------------|----|
| 39 | Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. <i>International Journal of Cancer</i> , 1998 , 76, 797-800 | 7.5 | 40 |
| 38 | Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis. <i>Journal of Cellular Biochemistry</i> , 2001 , 82, 619-33 | 4.7 | 40 |
| 37 | Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. Journal of Medicinal Chemistry, 2011 , 54, 8471-89 | 8.3 | 39 |
| 36 | Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. <i>Molecular Therapy</i> , 2008 , 16, 599-606 | 11.7 | 38 |
| 35 | Genetic instability leads to loss of both p53 alleles in a human glioblastoma. <i>Oncogene</i> , 1998 , 16, 321-6 | 9.2 | 33 |
| 34 | Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 5528-32 | 2.9 | 32 |
| 33 | Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. | 3.4 | 31 |
| 32 | Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 2206-221 | 8 ^{12.9} | 29 |
| 31 | Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. <i>Clinical Cancer Research</i> , 2016 , 22, 6256-6265 | 12.9 | 28 |
| 30 | KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. <i>PLoS ONE</i> , 2012 , 7, e44883 | 3.7 | 26 |
| 29 | Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clinical Cancer Research, 2006, 12, 2716-29 | 12.9 | 25 |
| 28 | BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. <i>Cancer Cell</i> , 2018 , 33, 1004-1016.e5 | 24.3 | 24 |
| 27 | SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. <i>Oncotarget</i> , 2014 , 5, 970 | 13 ,.9 | 24 |
| 26 | Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. <i>Clinical Cancer Research</i> , 2018 , 24, 6471-6482 | 12.9 | 24 |
| 25 | A role for activated Cdc42 in glioblastoma multiforme invasion. <i>Oncotarget</i> , 2016 , 7, 56958-56975 | 3.3 | 22 |
| 24 | BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. <i>Clinical Cancer Research</i> , 2017 , 23, 1809-1819 | 12.9 | 20 |
| 23 | Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. <i>Journal of Neuro-Oncology</i> , 1995 , 26, 191-8 | 4.8 | 20 |

| 22 | A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresis. <i>Scientific Reports</i> , 2019 , 9, 4437 | 4.9 | 18 |
|----|---|------|----|
| 21 | p53 and the CNS: tumors and developmental abnormalities. <i>Molecular Neurobiology</i> , 1999 , 19, 61-77 | 6.2 | 18 |
| 20 | Cancer therapy: Neutrophils traffic in cancer nanodrugs. <i>Nature Nanotechnology</i> , 2017 , 12, 616-618 | 28.7 | 16 |
| 19 | Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. <i>ACS Medicinal Chemistry Letters</i> , 2012 , 3, 620-5 | 4.3 | 15 |
| 18 | At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. <i>Journal of Molecular Medicine</i> , 2011 , 89, 91-4 | 5.5 | 15 |
| 17 | EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. <i>Oncogene</i> , 2020 , 39, 1041-1048 | 9.2 | 14 |
| 16 | Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis. <i>International Journal of Cancer</i> , 2001 , 94, 35-43 | 7.5 | 12 |
| 15 | Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020 , 1, | 18 | 11 |
| 14 | Two new species of betatorqueviruses identified in a human melanoma that metastasized to the brain. <i>Oncotarget</i> , 2017 , 8, 105800-105808 | 3.3 | 11 |
| 13 | Identification of nude mice in tumorigenicity assays. <i>International Journal of Cancer</i> , 1997 , 71, 310 | 7.5 | 10 |
| 12 | The expanding functional roles and signaling mechanisms of adhesion G protein-coupled receptors. <i>Annals of the New York Academy of Sciences</i> , 2019 , 1456, 5-25 | 6.5 | 7 |
| 11 | A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. <i>Oncotarget</i> , 2017 , 8, 99245-99260 | 3.3 | 7 |
| 10 | The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021 , 12, 1749 | 17.4 | 7 |
| 9 | Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017 , 32, 992-1001 | 5.6 | 6 |
| 8 | A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis. <i>Clinical Cancer Research</i> , 2020 , 26, 2711-2724 | 12.9 | 4 |
| 7 | Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. <i>Oncogene</i> , 2021 , 40, 5182-5191 | 9.2 | 3 |
| 6 | Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses 1998 , 79, 640 | | 3 |
| 5 | Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. <i>Bio-protocol</i> , 2017 , 7, | 0.9 | 1 |

| 4 | Mice lacking full length Adgrb1 (Bai1) exhibit social deficits, increased seizure susceptibility, and altered brain development <i>Experimental Neurology</i> , 2022 , 351, 113994 | 5.7 | 0 |
|---|---|------|---|
| 3 | Ten-eleven translocation protein 1 modulates medulloblastoma progression. <i>Genome Biology</i> , 2021 , 22, 125 | 18.3 | 0 |
| 2 | The advent of precision epigenetics for medulloblastoma. <i>Oncoscience</i> , 2020 , 7, 47-48 | 0.8 | |
| 1 | CBMS-7 IGF1/N-cadherin/Clusterin signaling axis mediates adaptive radioresistance of glioma stem cells. <i>Neuro-Oncology Advances</i> , 2021 , 3, vi3-vi3 | 0.9 | |